ReviewCurrent issues in molecular biology2026
UPP1 in Cancer: Context-Dependent Roles in Metabolic Adaptation and Treatment Response.
Review in Current issues in molecular biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Uridine phosphorylase 1 (UPP1) catalyzes the reversible phosphorolysis of uridine to uracil and ribose-1-phosphate, thereby linking pyrimidine salvage to central carbon metabolism. In cancer, UPP1 is functionally relevant when UPP1-linked pathway engagement and a perturbation-dependent phenotype converge within a defined cellular, nutrient/substrate, molecular, or treatment setting. The direction of effect is determined by the dominant biochemical or signaling output, whereas the strength of UPP1 dependence may be attenuated by compensation through related nucleoside-metabolic pathways. This review examines the roles of UPP1 in metabolic adaptation under nutrient stress, remodeling of the tumor microenvironment, and treatment response across cancer types. The strongest evidence concerns uridine-derived ribose-carbon utilization under glucose limitation and modulation of fluoropyrimidine response by UPP1. Mechanistic support for immune and microenvironmental effects is strongest in lung adenocarcinoma and selected metabolite-centered models, whereas most patient-outcome and pan-cancer findings remain cohort- or signature-based. This heterogeneity argues against treating UPP1 as a universal oncogenic driver or a stand-alone pan-cancer biomarker. Its biological and translational value lies in identifying tumor states in which UPP1-linked metabolism becomes functionally important or therapeutically informative.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.